In contrast to the control group, the 5‐year incidence of chronic GVHD (cGVHD) was lower (p = 0.018), and GVHD progression‐free survival (GPFS) was better (p = 0.025) in the IL‐2 group. Here, IL2 is linked to graft versus host disease.